Chemotherapy advances pinpoint mutations for more personalized care

Posted by  | treatment

Chemotherapy is a systemic therapy, and “in the past, lung cancer treatment was really a one-size-fits-all care,” says Russell K. Hales, M.D.  “Thanks to advances in treatment, we’ve been able to transition to more personalized care.  We can assess the tumor for changes that can be targeted with customized therapy, also known as molecular profiling. (...)

Melanoma drug FDA approved

Posted by  | treatment

This week, the FDA approved a new therapy called talimogene laherparepvec, which goes by the trade name, Imlygic, for the treatment of certain types of melanoma. Suzanne Topalian, M.D., professor of surgery and oncology, and director of the melanoma program at the Johns Hopkins Kimmel Cancer Center offered the following insights on the drug's approval: “This approval(...)

“We fight two battles to control lung cancer”

Posted by  | treatment

Medical teams at the Johns Hopkins Kimmel Cancer Center on the Johns Hopkins Bayview campus “have to fight two battles in order to control the cancer,” says radiation oncologist says Russell K. Hales, M.D. “The first is the local disease. A lung tumor is problematic, because as it grows, it can cause shortness of breath,(...)